Afinitor Package Insert Pdf

HIGHLIGHTS OF PRESCRIBING INFORMATION ...
3 • The recommended initial doseis 400mg/m2administered as a 120-minute intravenous infusion. • The recommended subsequent dosage (all other infusions) is 250mg/m2weekly as a60-minuteinfusionuntil disease progression or unacceptable toxicity. ... Get Doc

HIGHLIGHTS OF PRESCRIBING INFORMATION Proteinuria: Monitor ...
Refer to everolimus prescribing information for recommended everolimus dosing information. 2.4 Recommended Dosage for Hepatocellular Carcinoma (HCC) The recommended dosage of LENVIMA is based on actual body weight: • 12 mg for patients greater than or equal to 60 kg or • 8 mg for patients less than 60 kg. ... Read More

SPECIALTY GUIDELINE MANAGEMENT - Files.nc.gov
A. Breast Cancer Authorization of 12 months may be granted for treatment of HR-positive, HER2-negative recurrent or metastatic breast cancer when prescribed in combination with exemestane and any of the following criteria ... Document Retrieval

See Full Prescribing Information For Complete Boxed Warning ...
FULL PRESCRIBING INFORMATION WARNING: HEPATOTOXICITY Severe and sometimes fatal hepatotoxicity has occurred in clinical trials [see Warnings and Precautions (5.1)]. Monitor hepatic function prior to and during treatment [see Warnings and Precautions (5.1)]. ... Fetch Doc

These Highlights Do Not Include All The ... - Accessdata.fda.gov
Afinitor and afinitor disperz are indicated in adult and pediatric patients aged 1 year and older with TSC for the treatment of SEGA that requires therapeutic intervention but cannot be curatively resected. ... Doc Retrieval

Package Leaflet: Information For The Patient Afinitor
Package leaflet: Information for the patient Afinitor is an anticancer medicine containing the active substance everolimus. Everolimus reduces the blood supply to the tumour and slows down the growth and spread of cancer cells. ... Read Document

HIGHLIGHTS OF PRESCRIBING INFORMATION Do Not Administer To ...
Noxafil delayed-release tablets and Noxafil oral suspension Patients who have severe diarrhea or vomiting should be monitored closely for breakthrough fungal infectionswhen receiving Noxafil delayed-release tablets or oral suspension. ... View This Document

WARNINGS AND PRECAUTIONS-------------------- AFINIT
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Hormone Receptor-Positive, HER2-Negative Breast Cancer AFINITOR® is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2- negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. ... Document Viewer

Reference ID: 2857488 5.4 Laboratory Tests And Monitoring
AFINITOR is a kinase inhibitor indicated for the treatment of patients with: •advanced renal cell carcinoma (RCC) after failure of treatment with •subependymal giant cell astrocytoma (SEGA) associated with tuberous ... Access Full Source

Everolimus (Afinitor®) กลไกการออกฤทธิ์ของสารยับยั้งกำเนิดหลอดเลือด - Bevacizumab จะจับกับ VEGF ... Read Article

HIGHLIGHTS OF PRESCRIBING INFORMATION These Highlights Do Not ...
NDA 021923 FDA Approved 06Dec2018 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NEXAVAR safely and effectively. ... Fetch Content

HIGHLIGHTS OF PRESCRIBING INFORMATION The Dose For RA In ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RITUXAN safely and effectively. See full prescribing information for ... View Document

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
Afinitor plus exemestane suggested that an alcohol-free corticosteroid oral solution, administered as a mouthwash during the initial 8 weeks of treatment, may decrease the incidence and severity of stomatitis (see section 5.1). ... Fetch Document

HIGHLIGHTS OF PRESCRIBING INFORMATION ABRAXANE
ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic nonsmall cell lung cancer- , in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. ... Document Viewer

HIGHLIGHTS OF PRESCRIBING INFORMATION First-Line Non Squamous ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AVASTIN safely and effectively. See full prescribing information for ... Content Retrieval

AFINITOR® (everolimus) Oral Tablet AFINITOR® DISPERZ ...
Afinitor and Afinitor Disperz. Package Insert. Revised by manufacturer 9/2017. Accessed 02-26-2018. Afinitor and Afinitor Disperz. Package Insert. Revised by manufacturer 6/2016. Accessed 02-14-2017. Afinitor and Afinitor Disperz. Package Insert. Revised by manufacturer 2/2016. ... Get Document

HIGHLIGHTS OF PRESCRIBING INFORMATION ...
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Advanced Neuroendocrine Tumors of Pancreatic Origin (PNET) AFINITOR® is indicated for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease. ... Get Doc

AFINITOR - Swog.org
AFINITOR® (everolimus) is an oral mammalian target of rapamycin (mTOR) inhibitor that has been approved by the Food and Drug Administration for the following oncology indications1: • Treatment of postmenopausal women with advanced hormone ... View Doc

Angiogenesis Inhibitor - Wikipedia
An angiogenesis inhibitor is a substance that inhibits the growth of new blood vessels (angiogenesis). Some angiogenesis inhibitors are endogenous and a normal part of the body's control and others are obtained exogenously through pharmaceutical drugs or diet . ... Read Article

1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CYRAMZAsafely and effectively. See full prescribing information ... Fetch Content